ABSTRACT
Generalized pustular psoriasis (GPP) is a potentially life-threatening skin disease. Although several medications are approved for treating GPP in Japan, there are limited data on real-world treatment patterns or drug survival (the number of prescribed days of treatment). This retrospective cohort study describes drug survival and treatment patterns of patients with newly diagnosed GPP (International Classification of Diseases, 10th Revision code L40.1), and ≥1 year of follow-up, using de-identified claims data (Medical Data Vision Co., Ltd.) from January 2016 to August 2021. Most (97.0%) of the 434 Japanese patients received first-line therapy of etretinate (26.4%), topical medications (14.7%), or cyclosporin (14.3%); 80.0% and 60.1% of patients received a second and third line of therapy (LOT), respectively. Use of etretinate (12.6%) and cyclosporin (5.9%) decreased in second-line therapies, whereas use of biologics (interleukin [IL]-17, 14.3%; IL-23 inhibitors, 7.6%) and topical medications (22.1%) increased or remained consistent. Approximately 50% of biologics were prescribed in combination with systemic medications or systemic corticosteroids. Median (range) time to next therapy (TTNT) was 2.8 (0.03-48.07) months for first-line therapy and 3.3 (0.03-52.97) months for all other LOTs. TTNT was longer for combination therapies (up to 16.5 months) compared with monotherapies (up to 7.5 months). Biologics exhibited longer drug survival with fewer treatment episodes compared with non-biologic systemic medications. Among frequently used therapies, the median (95% confidence interval) drug survival was 8.8 (5.8-11.8) months for etretinate, 4.3 (2.2-6.9) months for systemic corticosteroids, and 19.6 (16.1-26.7) months for secukinumab. Treatment patterns varied considerably, highlighting the need for treatment algorithms and effective, well-tolerated medications to support patients to help them remain on long-term therapy.
Subject(s)
Biological Products , Cyclosporins , Etretinate , Psoriasis , Humans , Etretinate/therapeutic use , Japan , Retrospective Studies , Psoriasis/drug therapy , Biological Products/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Cyclosporins/therapeutic useABSTRACT
The Japanese Society for Psoriasis Research (JSPR) has been conducting annual epidemiological surveys of patients with pustular psoriasis in Japan since 2017. This study aimed to conduct a recent epidemiological analysis of patients with pustular psoriasis who were enrolled in the JSPR from 2017 to 2020. A total of 291 patients from 131 medical institutions were enrolled, of which 47.4% (138 cases) were males and 52.6% (153 cases) were females. The mean ± standard deviation (SD) age of the patients was 57.4 ± 20.3 years (males, 61.2 ± 17.3 years; females, 54.1 ± 22.1 years). The mean ± SD age of the patients at disease onset was 48.5 ± 22.5 years (males, 50.8 ± 20.6 years; females, 46.4 ± 24.0 years). The types of pustular psoriasis observed included the von Zumbusch type (59.8%), annular pustular psoriasis (8.2%), impetigo herpetiformis (6.5%), and acrodermatitis continua of Hallopeau (4.8%), of which, the majority of the patients with impetigo herpetiformis were female. Among the patients, 58.4% were treated with oral medications and 44.0% were treated with biologics. The most common oral medication prescribed was etretinate (52.4%), followed by corticosteroids (24.7%) and cyclosporin (22.9%). The most common biologics used were IL-17 inhibitors (ixekizumab [28.1%] and secukinumab [22.7%]), followed by tumor necrosis factor (TNF) inhibitors (infliximab [15.6%]) and IL-23 inhibitors (guselkumab [14.8%] and risankizumab [10.2%]). This survey thus provides new and significant information regarding the recent perspective of pustular psoriasis, such as patient characteristics and treatment trends, in Japan.
Subject(s)
Biological Products , Etretinate , Exanthema , Impetigo , Psoriasis , Skin Diseases, Vesiculobullous , Humans , Male , Female , Adult , Middle Aged , Aged , Impetigo/drug therapy , East Asian People , Psoriasis/drug therapy , Etretinate/therapeutic use , Biological Products/therapeutic use , Exanthema/drug therapy , Skin Diseases, Vesiculobullous/drug therapyABSTRACT
The systemic treatment of psoriasis has changed markedly with the introduction of many novel drugs. However, clinicians have had limited opportunities to evaluate these new therapies. One of the new drugs, apremilast (a phosphodiesterase-4 inhibitor), was approved in 2017 in Japan. We previously reported oral treatment for psoriasis before the introduction of apremilast. In this study, we investigated the impact of apremilast on oral medication for psoriasis by comparing data obtained before and after apremilast became available. This retrospective study enrolled patients who visited the Department of Dermatology, Fukuoka University Hospital, who were diagnosed with psoriasis and treated with anti-psoriatic oral medications. Patients were divided into two groups: Group 1, who first visited our clinic between January 2010 and March 2016; and Group 2, who first visited our clinic between April 2016 and March 2022. The information collected included patient demographics, drug use (apremilast, cyclosporine, methotrexate, and etretinate), and treatment duration. In Group 1 (n = 149 patients), cyclosporine, methotrexate, and etretinate were prescribed to 59.1%, 16.6%, and 24.3% of the patients, respectively. In Group 2 (n = 129 patients), apremilast was prescribed to 52.5% of patients, while the number of prescriptions for cyclosporine and etretinate had decreased to 17.1% and 8.3%, respectively. The number of methotrexate prescriptions did not change significantly. Apremilast, methotrexate, and etretinate had longer continuation rates than cyclosporine in Group 2. In conclusion, apremilast replaced cyclosporine and etretinate mainly because of its better safety profile, whereas methotrexate remained in constant demand in both eras. New oral treatments for psoriasis, such as tyrosine kinase-2 inhibitors, are now in the pipeline, and our data will serve as a control for oral anti-psoriatic medicine before the coming era.
Subject(s)
Etretinate , Phosphodiesterase 4 Inhibitors , Psoriasis , Humans , Retrospective Studies , Methotrexate/therapeutic use , Etretinate/therapeutic use , Psoriasis/drug therapy , Psoriasis/diagnosis , Cyclosporine/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Severity of Illness IndexSubject(s)
Acute Generalized Exanthematous Pustulosis/drug therapy , Antirheumatic Agents/adverse effects , Etretinate/therapeutic use , Hydroxychloroquine/adverse effects , Lupus Erythematosus, Systemic/drug therapy , Acute Generalized Exanthematous Pustulosis/diagnosis , Acute Generalized Exanthematous Pustulosis/etiology , Acute Generalized Exanthematous Pustulosis/pathology , Adult , Biopsy , Female , Humans , Skin/drug effects , Skin/pathology , Treatment OutcomeABSTRACT
Cutaneous-type adult T-cell leukemia-lymphoma is treated with antiviral or skin-directed therapy. Medications that are used to treat skin lesions of cutaneous T-cell lymphomas are also used for the cutaneous-type adult T-cell leukemia-lymphoma. Etretinate, a synthetic retinoid, has been used for treating cutaneous T-cell lymphomas; however, its clinical effectiveness for the treatment of cutaneous-type adult T-cell leukemia-lymphoma has not been fully studied. We conducted a retrospective assessment of the efficacy and safety of etretinate in 9 patients with cutaneous-type adult T-cell leukemia-lymphoma. Complete and partial responses to etretinate were observed in 1 and 7 patients, respectively. Among the responders, remission was maintained for more than 6 years in 2 patients. These results suggest that etretinate is a promising treatment option for cutaneous-type adult T-cell leukemia-lymphoma.
Subject(s)
Antineoplastic Agents/therapeutic use , Etretinate/therapeutic use , Leukemia-Lymphoma, Adult T-Cell/drug therapy , Lymphoma, T-Cell, Cutaneous/drug therapy , Skin Neoplasms/drug therapy , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Chemotherapy, Adjuvant , Etretinate/adverse effects , Female , Humans , Leukemia-Lymphoma, Adult T-Cell/pathology , Lymphoma, T-Cell, Cutaneous/pathology , Male , Middle Aged , PUVA Therapy , Retrospective Studies , Skin Neoplasms/pathology , Time Factors , Treatment Outcome , Ultraviolet TherapySubject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Etretinate/therapeutic use , Plant Extracts/therapeutic use , Skin Neoplasms/drug therapy , Administration, Oral , Aged, 80 and over , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/pathology , Female , Humans , Lip/pathology , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Treatment OutcomeSubject(s)
Dermatologic Agents/therapeutic use , Immunoglobulin G4-Related Disease/complications , Immunoglobulin G/blood , Psoriasis/immunology , Adalimumab/therapeutic use , Aged , Cyclosporine/therapeutic use , Drug Therapy, Combination/methods , Etretinate/therapeutic use , Female , Humans , Immunoglobulin G/immunology , Immunoglobulin G4-Related Disease/blood , Immunoglobulin G4-Related Disease/diagnostic imaging , Immunoglobulin G4-Related Disease/immunology , Magnetic Resonance Imaging , Male , Prednisolone/therapeutic use , Psoriasis/blood , Psoriasis/drug therapy , Psoriasis/pathology , Skin/pathology , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
Harlequin ichthyosis (HI) is the most severe form of autosomal recessive congenital ichthyosis, with a high mortality rate. Recent advances in neonatal care and the early administration of retinoids have improved the survival rate of HI. Here, we present a case of HI who was successfully treated with early administration of etretinate and showed good prognosis. Next-generation sequencing identified novel mutations of the ATP-binding cassette subfamily A member 12 gene (ABCA12), c.5884+4_+5delAA and c.7239G>A, which caused skipping of exons 39 and 48, respectively. Transcripts with exon 48 skipping, which cause a deletion in the second ATP-binding cassette of ABCA12, were dominantly expressed in the skin. Besides the early administration of etretinate, the differential expression of the mutant protein with limited segmental deletion of ABCA12 may be related to the favorable outcome of our patient.
Subject(s)
ATP-Binding Cassette Transporters/genetics , Ichthyosis, Lamellar/drug therapy , Ichthyosis, Lamellar/genetics , Keratolytic Agents/therapeutic use , Alternative Splicing/genetics , Biopsy , Etretinate/therapeutic use , Exons/genetics , High-Throughput Nucleotide Sequencing , Humans , Infant, Newborn , Male , Sequence Analysis, DNA , Sequence Deletion/genetics , Skin/pathologySubject(s)
Etretinate/therapeutic use , Keratoacanthoma/therapy , Keratolytic Agents/therapeutic use , Neoplasm Recurrence, Local/therapy , Skin Neoplasms/therapy , Skin/pathology , Transplants/pathology , Administration, Oral , Aged, 80 and over , Antineoplastic Agents/administration & dosage , Calcitriol/administration & dosage , Calcitriol/analogs & derivatives , Dermatologic Surgical Procedures , Drug Resistance, Neoplasm , Female , Humans , Keratoacanthoma/pathology , Leg , Neoplasm Recurrence, Local/pathology , Ointments , Skin Neoplasms/pathology , Skin Transplantation/adverse effects , Transplants/surgery , Treatment OutcomeSubject(s)
Darier Disease/complications , Esophageal Diseases/etiology , Acyclovir/analogs & derivatives , Acyclovir/therapeutic use , Antiviral Agents/therapeutic use , Biopsy , Darier Disease/drug therapy , Esophageal Diseases/drug therapy , Esophagoscopy , Etretinate/therapeutic use , Humans , Keratolytic Agents/therapeutic use , Male , Middle Aged , Valacyclovir , Valine/analogs & derivatives , Valine/therapeutic useABSTRACT
Punctate palmoplantar keratoderma type 1 (PPKP1) is a rare autosomal dominant disorder of keratinization, clinically characterized by punctate keratotic papules affecting the palmoplantar skin. Loss-of-function mutations in AAGAB have recently been reported as a cause of PPKP1. Despite the discovery of the genetic cause of PPKP1, pathogenesis-based therapies are still unavailable. Moreover, little is known about the effectiveness of treatments for PPKP1. In this study, we analyzed a Japanese woman with PPKP1 and identified a novel frame-shift mutation c.195_198del4 (p.Lys66Phefs*43) in AAGAB. Moreover, low-dose etretinate was effective in improving the PPKP1 lesions in our patient. Our published work review identified only eight cases of PPKP1 with successful response to topical or systemic treatments. Notably, six of the cases were successfully treated with systemic retinoids. Thus, this study clearly provides further evidence that PPKP1 is caused by AAGAB mutations and that systemic retinoids are the most promising current treatment for PPKP1.
Subject(s)
Etretinate/therapeutic use , Keratoderma, Palmoplantar/drug therapy , Keratolytic Agents/therapeutic use , Adaptor Proteins, Vesicular Transport/genetics , Female , Humans , Keratoderma, Palmoplantar/genetics , Keratoderma, Palmoplantar/pathology , Middle Aged , Skin/pathologySubject(s)
Adaptor Proteins, Vesicular Transport/genetics , Etretinate/therapeutic use , Keratoderma, Palmoplantar/drug therapy , Keratoderma, Palmoplantar/genetics , Keratolytic Agents/therapeutic use , Mutation , Aged, 80 and over , Biopsy , DNA Mutational Analysis , Female , Genetic Predisposition to Disease , Humans , Immunohistochemistry , Keratoderma, Palmoplantar/diagnosis , Phenotype , Remission Induction , Treatment OutcomeSubject(s)
Alopecia/diagnosis , Alopecia/genetics , Codon, Nonsense , Hyperpigmentation/diagnosis , Hyperpigmentation/genetics , Nail Diseases/diagnosis , Nail Diseases/genetics , Skin Neoplasms/diagnosis , Skin Neoplasms/genetics , Adult , Alopecia/drug therapy , Etretinate/therapeutic use , Female , Humans , Hyperpigmentation/drug therapy , Keratolytic Agents/therapeutic use , Male , Nail Diseases/drug therapy , Siblings , Skin Neoplasms/drug therapy , Treatment OutcomeABSTRACT
BACKGROUND: Acitretin is indicated for severe psoriasis, but it is also a potent teratogen whose use should be avoided in women of childbearing potential. Topical medications, phototherapy, cyclosporine A, and new biologic agents provide safer alternatives for women of childbearing age with moderate to severe psoriasis. PURPOSE: To determine the demographics of acitretin prescribing patterns as an assessment of acitretin use in women of child-bearing potential. METHODS: We examined National Ambulatory Medical Care Survey (NAMCS) data from the years 1990-2009 to determine demographic data on patients who were prescribed etretinate or acitretin. We used age under 50 as a proxy for childbearing potential. RESULTS: From 1996-2009, there were an estimated 29 million office visits for psoriasis. Females accounted for 14.3 million of these visits, and 6.5 million (45.6%) of them were under the age of 50. The NAMCS contained only one record of a female patient under the age of 50 being prescribed acitretin from 1996-2009, the years during which acitretin had been available in the United States. This corresponds to an estimated 2.3% of all psoriasis patients prescribed acitretin during this time (20,000 out of 890,000). LIMITATIONS: The NAMCS estimates national trends based on a large nationwide database. While the use of acitretin in women under 50 is low, the precision of the estimate is limited by the small sample size provided by this database. CONCLUSIONS: There are now many alternative treatments besides acitretin for women of childbearing potential with moderate to severe psoriasis. Acitretin is used at most infrequently in this population. In females of reproductive potential, acitretin should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments.
Subject(s)
Acitretin/administration & dosage , Etretinate/administration & dosage , Keratolytic Agents/administration & dosage , Practice Patterns, Physicians'/statistics & numerical data , Acitretin/adverse effects , Acitretin/therapeutic use , Adult , Age Factors , Aged , Databases, Factual , Etretinate/adverse effects , Etretinate/therapeutic use , Female , Health Care Surveys , Humans , Keratolytic Agents/adverse effects , Keratolytic Agents/therapeutic use , Male , Middle Aged , Psoriasis/drug therapy , Severity of Illness Index , United StatesSubject(s)
Mycosis Fungoides/therapy , Adult , Antineoplastic Agents/therapeutic use , Combined Modality Therapy , Electrons/therapeutic use , Etretinate/therapeutic use , Female , Humans , Interferon-gamma/therapeutic use , Keratolytic Agents/therapeutic use , PUVA Therapy , Remission Induction/methodsABSTRACT
A 68-year-old Japanese woman was referred to our hospital with a 1-year history of multiple erosions on the oral mucosa and a few pruritic, bean-sized, reddish-blue plaques on the body. Based on physical examination, pathological findings, and immunofluorescence findings, a diagnosis of lichen planus (LP) was made. Computed tomography scan revealed a thymoma. After thymectomy, cutaneous LP lesions subsided spontaneously. Oral lesions responded well to oral etretinate therapy. We speculate that direct tissue injury by CD8(+) T cells, activated by abnormal regulation of lymphocytes within the thymus, may cause LP.
Subject(s)
Etretinate/therapeutic use , Keratolytic Agents/therapeutic use , Lichen Planus, Oral/drug therapy , Lichen Planus, Oral/etiology , Thymoma/complications , Thymus Neoplasms/complications , Aged , Female , Humans , Lichen Planus, Oral/diagnosis , Thymoma/diagnosis , Thymoma/therapy , Thymus Neoplasms/diagnosis , Thymus Neoplasms/therapyABSTRACT
Various therapies have been tried for psoriasis. In Japan, biologics began to be used for psoriasis treatment in January 2010. Their clinical efficacy is well known, but biologics cannot be used in all psoriasis patients for reasons such as side-effects and cost. It is necessary to evaluate the effect of long-term psoriasis treatment, but there have been no reports evaluating long-term treatment. Therefore, the outcomes of patients who had been treated at the Tokai University Hospital for more than 5 years, before biological agents were released, were examined. Three categories, classified by initial severity, changes in severity by method of treatment and background characteristics, were investigated. In conclusion, cases of long-term treatment with a combination of topical corticosteroid and topical vitamin D3 analog or oral cyclosporin were found to be effective therapies. Patients with a history of diabetes mellitus or cardiovascular disease of psoriasis were likely to be treatment resistant.